Although the rates of progression-free survival are steadily increasing, the majority of multiple myeloma (MM) patients still face relapse. Here, Neil van de Donk, MD, PhD, of VU University Medical Centre, Amsterdam, Netherlands, considers approaches for improving the cure rate of MM; from introducing earlier more active agents, to achieving measurable residual disease (MRD) negativity. He also highlights promising therapies for future testing. This interview took place at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
Improving the cure rate of multiple myeloma
